Rosaria Volpini

5.1k total citations · 1 hit paper
164 papers, 4.1k citations indexed

About

Rosaria Volpini is a scholar working on Physiology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Rosaria Volpini has authored 164 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Physiology, 105 papers in Molecular Biology and 54 papers in Organic Chemistry. Recurrent topics in Rosaria Volpini's work include Adenosine and Purinergic Signaling (118 papers), Receptor Mechanisms and Signaling (57 papers) and Pharmacological Receptor Mechanisms and Effects (37 papers). Rosaria Volpini is often cited by papers focused on Adenosine and Purinergic Signaling (118 papers), Receptor Mechanisms and Signaling (57 papers) and Pharmacological Receptor Mechanisms and Effects (37 papers). Rosaria Volpini collaborates with scholars based in Italy, Germany and United States. Rosaria Volpini's co-authors include Catia Lambertucci, Gloria Cristalli, Diego Dal Ben, Sauro Vittori, Gabriella Marucci, Michela Buccioni, Stefano Costanzi, Francesco Amenta, Karl‐Norbert Klotz and Emidio Camaioni and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Biochemistry.

In The Last Decade

Rosaria Volpini

160 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

2020 736 citations Gabriella Marucci, Michela Buccioni et al. profile →

Peers

Countries citing papers authored by Rosaria Volpini

Since Specialization

Citations

This map shows the geographic impact of Rosaria Volpini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosaria Volpini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosaria Volpini more than expected).

Fields of papers citing papers by Rosaria Volpini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosaria Volpini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosaria Volpini. The network helps show where Rosaria Volpini may publish in the future.

Co-authorship network of co-authors of Rosaria Volpini

This figure shows the co-authorship network connecting the top 25 collaborators of Rosaria Volpini. A scholar is included among the top collaborators of Rosaria Volpini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosaria Volpini. Rosaria Volpini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Radioligands Targeting the Purinergic P2X Receptors 2025 ·Cells ·Diego Dal Ben, Michela Buccioni, Catia Lambertucci, (unknown), (unknown), Andrea Spinaci, Gabriella Marucci, Rosaria Volpini	1
2	“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 2023 ·Pharmaceuticals ·Andrea Spinaci, Michela Buccioni, Daniela Catarzi, Chang Cui, Vittoria Colotta, Diego Dal Ben, (unknown), (unknown), (unknown), Catia Lambertucci, Gabriella Marucci, Davide Bassani, Matteo Pavan, Flavia Varano, Stephanie Federico, Giampiero Spalluto, Stefano Moro, Rosaria Volpini	9
3	Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A2A Adenosine Receptor Useful in Neurodegenerative Disorders 2023 ·Molecules ·(unknown), Simone Angeloni, Diego Dal Ben, Catia Lambertucci, Massimo Ricciutelli, Andrea Spinaci, (unknown), Rosaria Volpini, Michela Buccioni, Gabriella Marucci	1
4	A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 2022 ·Pharmaceuticals ·Andrea Spinaci, Michela Buccioni, Diego Dal Ben, Federica Maggi, Gabriella Marucci, (unknown), Giorgio Santoni, Catia Lambertucci, Rosaria Volpini	4
5	A_2A Adenosine Receptor Antagonists and their Potential in NeurologicalDisorders 2022 ·Current Medicinal Chemistry ·Catia Lambertucci, Gabriella Marucci, Daniela Catarzi, Vittoria Colotta, (unknown), Andrea Spinaci, Flavia Varano, Rosaria Volpini	13
6	4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives 2022 ·Pharmaceuticals ·Daniela Catarzi, Flavia Varano, (unknown), (unknown), Fabrizio Melani, Katia Varani, Fabrizio Vincenzi, Silvia Pasquini, Natascia Mennini, (unknown), Diego Dal Ben, Rosaria Volpini, Vittoria Colotta	5
7	A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 2022 ·Molecules ·Andrea Spinaci, Catia Lambertucci, Michela Buccioni, Diego Dal Ben, Claudia Graiff, Maria Cristina Barbalace, Silvana Hrelia, Cristina Angeloni, Seyed Khosrow Tayebati, Massimo Ubaldi, Alessio Masi, Karl‐Norbert Klotz, Rosaria Volpini, Gabriella Marucci	7
8	Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents forNeurodegenerative Disorders 2022 ·Current Medicinal Chemistry ·Daniela Catarzi, Flavia Varano, (unknown), Catia Lambertucci, Andrea Spinaci, Rosaria Volpini, Vittoria Colotta	12
9	Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A1 and A2A Receptors, and Efficacy in Animal Models of Depression 2021 ·Pharmaceuticals ·Flavia Varano, Daniela Catarzi, (unknown), Diego Dal Ben, Michela Buccioni, Gabriella Marucci, Lorenzo Di Cesare Mannelli, Elena Lucarini, Carla Ghelardini, Rosaria Volpini, Vittoria Colotta	5
10	New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 2020 ·Bioorganic & Medicinal Chemistry Letters ·Matteo Falsini, (unknown), Daniela Catarzi, Flavia Varano, Diego Dal Ben, Gabriella Marucci, Michela Buccioni, (unknown), Rosaria Volpini, Vittoria Colotta	5
11	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 2020 ·Cells ·Luca Antonioli, Elena Lucarini, Catia Lambertucci, Matteo Fornai, Carolina Pellegrini, Laura Benvenuti, Lorenzo Di Cesare Mannelli, Andrea Spinaci, Gabriella Marucci, Corrado Blandizzi, Carla Ghelardini, Rosaria Volpini, Diego Dal Ben	16
12	Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 2019 ·Bioorganic Chemistry ·Matteo Falsini, Daniela Catarzi, Flavia Varano, (unknown), Gabriella Marucci, Michela Buccioni, Rosaria Volpini, Lorenzo Di Cesare Mannelli, Carla Ghelardini, Vittoria Colotta	12
13	Regulation of adenosine A_2A receptor gene expression in a model of binge eating in the amygdaloid complex of female rats 2019 ·Journal of Psychopharmacology ·Maria Vittoria Micioni Di Bonaventura, Mariangela Pucci, (unknown), Adele Romano, Catia Lambertucci, Rosaria Volpini, Emanuela Micioni Di Bonaventura, Silvana Gaetani, Mauro Maccarrone, Claudio D’Addario, Carlo Cifani	21
14	Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 2019 ·Pharmaceuticals ·Diego Dal Ben, Catia Lambertucci, Michela Buccioni, (unknown), Gabriella Marucci, Andrea Spinaci, Rosaria Volpini	11
15	Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 2018 ·Bioorganic & Medicinal Chemistry Letters ·Flavia Varano, Daniela Catarzi, Matteo Falsini, Diego Dal Ben, Michela Buccioni, Gabriella Marucci, Rosaria Volpini, Vittoria Colotta	10
16	Anticancer activity study of A 3 adenosine receptor agonists 2018 ·Life Sciences ·Gabriella Marucci, (unknown), Michela Buccioni, (unknown), Catia Lambertucci, (unknown), Olli Yli‐Harja, Rosaria Volpini, Meenakshisundaram Kandhavelu	13
17	New substituted 9-propyladenine derivatives as A_2Aadenosine receptor antagonists 2015 ·MedChemComm ·Catia Lambertucci, Michela Buccioni, Diego Dal Ben, Sonja Kachler, Gabriella Marucci, Andrea Spinaci, Ajiroghene Thomas, Karl‐Norbert Klotz, Rosaria Volpini	9
18	Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor 2010 ·Purinergic Signalling ·Stefania Ceruti, Enrica Calleri, G. Cristalli, Claudia Martini, Caterina Temporini, Chiara Parravicini, Rosaria Volpini, Simona Daniele, Gabriele Caccialanza, Davide Lecca, Catia Lambertucci, (unknown), Gabriella Marucci, (unknown), Graziella Ranghino, Piercarlo Fantucci, Maria P. Abbracchio, Gabriella Massolini	2
19	Adenosine deaminase: Functional implications and different classes of inhibitors 2001 ·Medicinal Research Reviews ·Gloria Cristalli, Stefano Costanzi, Catia Lambertucci, Giulio Lupidi, Sauro Vittori, Rosaria Volpini, Emidio Camaioni	278
20	Pharmacology of the new selective A2a adenosine receptor agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine. 1994 ·PubMed ·Angela Monopoli, Andrea Conti, Cristina Zocchi, C Casati, Rosaria Volpini, Giovanni Cristalli, E. Ongini	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact